Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology

Rui Qin, Manish Kohli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The rapid evolution of molecular technologies that can identify genetic markers and lead to dissecting the inherent variance of individual cancer biology has had a tangible impact on trial designs in oncology. Rational trial designs based on molecular marker expression coupled with drug-marker interactions have started to be adopted, challenging the previous paradigms of morphology-based, single-arm efficacy studies. This review summarizes novel trials being developed based on molecular predictive factor therapeutics and the potential impact these novel trial designs will have on the practice of oncology in future. A variety of clinical trial designs based on tumor and drug-host genetic interactions are discussed and the example of advanced prostate cancer is used to illustrate the changing landscape of clinical trial designs in cancer.

Original languageEnglish (US)
Pages (from-to)859-869
Number of pages11
JournalPersonalized Medicine
Volume10
Issue number8
DOIs
StatePublished - Nov 2013

Fingerprint

Pharmacogenetics
Clinical Trials
Neoplasms
Molecular Evolution
Drug Interactions
Genetic Markers
Prostatic Neoplasms
Technology
Pharmaceutical Preparations
Therapeutics

Keywords

  • adaptive clinical trial
  • genomic signature
  • molecular profiling
  • pharmacogenetic
  • predictive biomarker

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. / Qin, Rui; Kohli, Manish.

In: Personalized Medicine, Vol. 10, No. 8, 11.2013, p. 859-869.

Research output: Contribution to journalArticle

@article{5fd725dc44324401afccb13b67f4074a,
title = "Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology",
abstract = "The rapid evolution of molecular technologies that can identify genetic markers and lead to dissecting the inherent variance of individual cancer biology has had a tangible impact on trial designs in oncology. Rational trial designs based on molecular marker expression coupled with drug-marker interactions have started to be adopted, challenging the previous paradigms of morphology-based, single-arm efficacy studies. This review summarizes novel trials being developed based on molecular predictive factor therapeutics and the potential impact these novel trial designs will have on the practice of oncology in future. A variety of clinical trial designs based on tumor and drug-host genetic interactions are discussed and the example of advanced prostate cancer is used to illustrate the changing landscape of clinical trial designs in cancer.",
keywords = "adaptive clinical trial, genomic signature, molecular profiling, pharmacogenetic, predictive biomarker",
author = "Rui Qin and Manish Kohli",
year = "2013",
month = "11",
doi = "10.2217/pme.13.78",
language = "English (US)",
volume = "10",
pages = "859--869",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology

AU - Qin, Rui

AU - Kohli, Manish

PY - 2013/11

Y1 - 2013/11

N2 - The rapid evolution of molecular technologies that can identify genetic markers and lead to dissecting the inherent variance of individual cancer biology has had a tangible impact on trial designs in oncology. Rational trial designs based on molecular marker expression coupled with drug-marker interactions have started to be adopted, challenging the previous paradigms of morphology-based, single-arm efficacy studies. This review summarizes novel trials being developed based on molecular predictive factor therapeutics and the potential impact these novel trial designs will have on the practice of oncology in future. A variety of clinical trial designs based on tumor and drug-host genetic interactions are discussed and the example of advanced prostate cancer is used to illustrate the changing landscape of clinical trial designs in cancer.

AB - The rapid evolution of molecular technologies that can identify genetic markers and lead to dissecting the inherent variance of individual cancer biology has had a tangible impact on trial designs in oncology. Rational trial designs based on molecular marker expression coupled with drug-marker interactions have started to be adopted, challenging the previous paradigms of morphology-based, single-arm efficacy studies. This review summarizes novel trials being developed based on molecular predictive factor therapeutics and the potential impact these novel trial designs will have on the practice of oncology in future. A variety of clinical trial designs based on tumor and drug-host genetic interactions are discussed and the example of advanced prostate cancer is used to illustrate the changing landscape of clinical trial designs in cancer.

KW - adaptive clinical trial

KW - genomic signature

KW - molecular profiling

KW - pharmacogenetic

KW - predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=84886454014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886454014&partnerID=8YFLogxK

U2 - 10.2217/pme.13.78

DO - 10.2217/pme.13.78

M3 - Article

AN - SCOPUS:84886454014

VL - 10

SP - 859

EP - 869

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 8

ER -